FINWIRES · TerminalLIVE
FINWIRES

HKG:7630

6 stories mentioning HKG:7630Updated 22d ago

Every FINWIRES story that references HKG:7630, newest first.

Asia

Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option

Impact Therapeutics (HKG:7630) said the overallotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.The Chinese biopharmaceutical company expects to raise about HK$119.5 million in additional net proceeds.The exercise involved the issue of 6.3 million additional H-shares at HK$20.10 each, representing about 15% of the total offer shares initially available under the global offering.Dealings in the overallotment shares are expected to begin on June 10, the filing said.

HKG:7630
Asia

Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut

Hong Kong stocks edged higher on Wednesday ahead of the meeting between U.S. President Donald Trump and Chinese President Xi Jinping.The Hang Seng Index added 0.2%, or 40.53 points, to close at 26,388.44. The Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,876.38.Trump is expected to arrive in Beijing on Wednesday ahead of talks scheduled for Thursday and Friday.The leaders of the world's two largest economies are set to hold their first face-to-face meeting in more than six months.Discussions are expected to focus on Iran, Taiwan, artificial intelligence, and nuclear weapons, while both sides also weigh extending their critical minerals agreement.Meanwhile, tensions in the Middle East remained unresolved after Trump said he was unlikely to seek China's assistance in ending the conflict with Iran.In corporate news, two companies made their debut on the Hong Kong bourse.Metis TechBio (HKG:7666) closed nearly 127% higher at HK$23.80, well above the offer price of HK$10.50.Impact Therapeutics (HKG:7630) advanced over 108% to close at HK$41.86, compared with the offer price of HK$20.10.

Hang SengHKG:7630HKG:7666
Asia

Impact Therapeutics Jumps 77% in Hong Kong Trading Debut

Impact Therapeutics' (HKG:7630) shares opened 76.6% above their initial public offering price in a solid Hong Kong debut on Wednesday morning.The Chinese biotech company opened at HK$35.50 per share, compared with the offer price of HK$20.10.

HKG:7630
Asia

Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut

Impact Therapeutics (HKG:7630) raised HK$759.5 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$20.10 per H-share, near the lower end of the offer price range, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The Chinese biotech company offered nearly 42 million H-shares in the global offering.The Hong Kong public offer was 2,282.4 times subscribed, with a final allocation of 4.2 million shares, representing 10% of the total offering.The international offering was 24.58 times subscribed, with a final allocation of 37.8 million shares, or 90% of the total offering.An over-allocation of 6.3 million shares was made under the global offering.Cornerstone investors, including Nanjing Biotech and Pharmaceutical Valley Construction and Development, Huang River Investment, and LAV Star, were allocated about 13.9 million shares representing 33.19% of the global offering, according to the filing.Impact Therapeutics is scheduled to debut on the Hong Kong bourse on Wednesday, May 13.

HKG:7630
Asia

Hong Kong Stocks Slump As Middle East Fighting Escalates

Hong Kong equities fell Tuesday as bearish sentiment prevailed amid escalating tensions in the Middle East.The Hang Seng Index fell by around 197.27 points, or roughly 0.8%, to end at 25,898.61, while the Hang Seng China Enterprises Index decreased by 43.90 points, or around 0.5%, to close at 8,730.49.Fighting in the Middle East resumed as the U.S. and Iran vied for control of the critical Strait of Hormuz, after U.S. President Donald Trump said Washington would help ships stranded in the waterway, a key route that carried about one-fifth of global oil and LNG trade before the war.Iran had previously warned it would view any such action as a violation of a previously agreed ceasefire.The Middle East conflict will hit many Asia-Pacific corporate sectors through oil price hikes, shipping and supply chain disruptions, dampened demand, and delayed cyclical rebounds, Fitch Ratings said in a recent release.In corporate news, two firms filed to go public in Hong Kong.Metis TechBio (HKG:7666) is seeking to raise about HK$2.11 billion via the sale of 201.2 million shares at HK$10.50 per share. The Chinese AI-driven nanotechnology company will use funds to further research and development of AI infrastructure.Meanwhile, Impact Therapeutics (HKG:7630) launched its IPO to raise HK$913 million via the sale of 42 million shares at an indicative maximum price of HK$21.75 per share. The China-based biotechnology firm will use proceeds mainly to fund clinical development.Elsewhere, Star Sports Medicine (HKG:1609) had a stellar debut in Hong Kong. The medical device company's shares closed at HK$215 per share on their first day of trading, 118% above the offer price of HK$98.50.

Hang SengHKG:1609HKG:7630HKG:7666
Asia

Impact Therapeutics Launches Up to HK$913 Million Hong Kong IPO

Impact Therapeutics (HKG:7630) launched its Hong Kong initial public offering on Tuesday, seeking to raise up to about HK$913 million from the deal.The China-based biotechnology company is offering 42 million shares at an indicative maximum price of HK$21.75 per share, according to a Hong Kong bourse filing.The offering comprises 4.2 million shares for Hong Kong investors and 37.8 million shares for international investors, subject to reallocation and the overallotment option.The offer price is expected to be determined by May 11, with allocation results due by May 12, ahead of the company's planned trading debut on May 13.Net proceeds will be used mainly to fund the clinical development, regulatory approval, and commercialization of its core product, senaparib, as well as support the development of key pipeline products.The funds will also be used for research and development of other pipeline assets, expansion of R&D platforms, and for working capital and general corporate purposes.Goldman Sachs (Asia) and China International Capital Corporation Hong Kong Securities are acting as joint sponsors.Goldman Sachs (Asia) and China International Capital Corporation Hong Kong Securities are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers.CMB International Capital is acting as a joint global coordinator and joint lead manager, while Tiger Brokers (HK) Global is acting as a joint bookrunner and joint lead manager.

HKG:7630

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:7630 in your portfolio
WheelAI
WheelAI
Analyze HKG:7630 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:7630